Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 5, 2015, Pages 577-596

  Kalra, Sanjay ^a   Aamir, A H ^b   Raza, Abbas ^c   Das, A K ^d   Khan, A K Azad ^e   Shrestha, Dina ^f   Qureshi, Md Faisal ^g   Fariduddin, Md ^h   Pathan, Md Faruque ⁱ   Jawad, Fatema ^j   Bhattarai, Jyoti ^k   Tandon, Nikhil ^l   Somasundaram, Noel ^m   Katulanda, Prasad ⁿ   Sahay, Rakesh ^o   Dhungel, Sanjib ^p   Bajaj, Sarita ^q   Chowdhury, Subhankar ^r   Ghosh, Sujoy ^s   Madhu, S V ^t   Ahmed, Tofail ^u   Bulughapitiya, Uditha ^v   more..

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

^b Hayatabad Medical Complex Hospital   (Pakistan)

^c SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^d PONDICHERRY INSTITUTE OF MEDICAL SCIENCES   (India)

^e BANGLADESH UNIVERSITY OF HEALTH SCIENCES   (Bangladesh)

^f Norvic International Hospital   (Nepal)

^g Al Khaliq Medicare Hospital   (Bangladesh)

^h BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

ⁱ BIRDEM Hospital   (Bangladesh)

^j Department of Diabetology   (Pakistan)

^k Trivuvan University   (Nepal)

^l ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^m National Hospital   (Bangladesh)

ⁿ UNIVERSITY OF COLOMBO   (Sri Lanka)

^o OSMANIA MEDICAL COLLEGE   (India)

^p NEPAL MEDICAL COLLEGE TEACHING HOSPITAL   (Nepal)

^q MLN MEDICAL COLLEGE   (India)

^r INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^s BANGUR INSTITUTE OF NEUROSCIENCES   (India)

^t UCMS AND GTB HOSPITAL   (India)

^u Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

^v Kalubowila South Teaching Hospital   (Sri Lanka)

more..

Author keywords

Anti hyperglycaemic agent; gliclazide; glimepiride; glipizide; safety; sulfonylurea; type 2 diabetes mellitus; vascular complications

Indexed keywords

EID: 84981244978     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.163171     Document Type: Review

References (162)

1. International Diabetes Federation. Key Findings; 2014. Available from: http://www.idf.org/diabetesatlas/update-2014. [Last accessed on 2015 Mar 25]
2. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-94
3. Kannan, Arshad, Senthil K. A study on drug utilization of oral hypoglycemic agents in type-2 diabetic patients. Asian J Pharm Clin Res 2011;5:60-4
4. Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm 2013;4:82-7
5. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003;26:1852-5
6. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 2004;164:1134-9
7. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003;26:1847-51
8. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008
9. Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm 2014;5:79-83
10. Ahmed QS, Sayedda K, Dharmender G, Ahmad AN. Prescribing patterns of Antidiabetic medications in a tertiary care teaching hospital, Bareilly, UP, India. J Pharm Sci Innov 2013;2:41-6
11. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: Quality and cost implications. Am J Med 2012;125:302.e1-7
12. National Essential Medicine List of Bangladesh. Ministry of Health and Family Welfare; 2008. Available from: http://www.who.int/ selection-medicines/country-lists/bgd-eml-2008.pdf. [Last accessed on 2015 Mar 25]
13. National List of Essential Medicines of India; 2011. Available from: http:// www.mohfw.nic.in/WriteReadData/l892s/7364497513National%20 List%20of%20Essential%20Medicine,%202011.pdf. [Last accessed on 2015 Mar 25]
14. National List of Essential Medicines of Nepal; 2011. Available from: http://www.searo.who.int/entity/medicines/neml-nep-2011- govtwebsite-ok.pdf. [Last accessed on 2015 Mar 25]
15. National Essential Medicine List of Pakistan. Ministry of Health. Government of Pakistan. Available from: http://www.apps.who.int/ medicinedocs/documents/s17119e/s17119e.pdf. [Last accessed on 2015 Mar 25]
16. National List of Essential Medicines Sri Lanka; 2009. Available from: http://www.apps.who.int/medicinedocs/documents/s16730e/ s16730e.pdf. [Last accessed on 2015 Mar 25]
17. Kalra S, Gupta Y, Saboo B. Essential drugs in diabetes: South and South East Asian perspective. J Soc Health Diabetes 2015;3:4-6
18. IMS Health; 2014. Available from: http://www.imshealth.com/portal/ site/imshealth. [Last accessed on 2015 Apr 01]
19. IMS TSA; 2014. Available from: http://www.imsbrogancapabilities. com/en/healthcare-tsa.html. [Last accessed on 2015 Apr 01]
20. Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India 2012;60:27-30
21. Abrar A, Khan S, Rehman MU, Jan T, Faisal M. Safety and efficacy of sitagliptin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Gomal J Med Sci 2013;11:3-7
22. Philippe J, Raccah D. Treating type 2 diabetes: How safe are current therapeutic agents? Int J Clin Pract 2009;63:321-32
23. Seltzer HS. Efficacy and safety of oral hypoglycemic agents. Annu Rev Med 1980;31:261-72
24. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP 4th, Boyd AE 3rd, González G, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995;268:423-6
25. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013;56:973-84
26. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
27. Basit A, Riaz M, Fawwad A. Glimepiride: Evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag 2012;8:463-72
28. Canaglifozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 2013;55:37-9
29. Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: A Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014;2:E162-75
30. Thulé PM, Umpierrez G. Sulfonylureas: A new look at old therapy. Curr Diab Rep 2014;14:473
31. Sehra D, Sehra S, Sehra ST. Sulfonylureas: Do we need to introspect safety again? Expert Opin Drug Saf 2011;10:851-61
32. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-6
33. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311:2288-96
34. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17 Suppl 2:1-53
35. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996;28:464-8
36. Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2010;6:225-35
37. Davis SN. The role of glimepiride in the effective management of Type 2 diabetes. J Diabetes Complications 2004;18:367-76
38. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: Mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17 2 Suppl: 11-5
39. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: Lessons from studies of cloned K (ATP) channels. J Diabetes Complications 2000;14:192-6
40. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000;49 10 Suppl 2:3-6
41. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K (ATP) channels. Br J Pharmacol 2001;133:193-9
42. Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J 2007;21:18-25
43. Winkler M, Stephan D, Bieger S, Kühner P, Wolff F, Quast U. Testing the bipartite model of the sulfonylurea receptor binding site: Binding of A-, B-, and A+B-site ligands. J Pharmacol Exp Ther 2007;322:701-8
44. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, et al. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride. Biochim Biophys Acta 1994;1191:278-90
45. Müller G, Hartz D, Pünter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191:267-77
46. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73
47. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607-11
48. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51 Suppl 3:S368-76
49. Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int 2014;111:69-81
50. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: Evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011;60:1-23
51. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
52. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
53. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
54. Zhu H, Zhu S, Zhang X, Guo Y, Shi Y, Chen Z, et al. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Diabetol Metab Syndr 2013;5:70
55. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34
56. McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther 2004;26:1783-90
57. Fritsche A, Schweitzer MA, Häring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9
58. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
59. Gitt AK, Bramlage P, Binz C, Schneider S, Krekler M, Tschoepe D. Outcome of sulfonylurea and insulin versus incretin-based treatment in type 2 diabetes patients uncontrolled on prior metformin mono therapy: Results of Dia Regis. J Am Coll Cardiol 2014;63 12 Suppl:A1336
60. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
61. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-406
62. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-206
63. Darlow BA. Symptomatic hyponatraemia associated with tolbutamide therapy. Postgrad Med J 1977;53:223-4
64. Harris EL. Adverse reactions to oral antidiabetic agents. Br Med J 1971;3:29-30
65. Campbell RK. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52
66. Gajos G, Pilacinski S, Zozulinska-Ziolkiewicz D. Controversies in diabetes in 2013-A brief update. Adv Clin Exp Med 2013;22:777-84
67. Barzilai N, Groop PH, Groop L, DeFronzo RA. A novel mechanism of glipizide sulfonylurea action: Decreased metabolic clearance rate of insulin. Acta Diabetol 1995;32:273-8
68. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999;84:3140-5
69. Mori RC, Hirabara SM, Hirata AE, Okamoto MM, Machado UF. Glimepiride as insulin sensitizer: Increased liver and muscle responses to insulin. Diabetes Obes Metab 2008;10:596-600
70. Li CJ, Zhang JY, Yu DM, Zhang QM. Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr 2014;6:41
71. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: A retrospective analysis. Diabetes Care 2010;33:1224-9
72. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103:3111-6
73. Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol 2014;13:15
74. Diamicron MR (Gliclazide). Product Monograph. Available from: http://www.servier.ca/sites/default/files/webform/Products/ EN-DIAMICRON-MR-PI.pdf. [Last accessed on 2015 Apr 01]
75. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44:215-22
76. Global Guideline for Type 2 Diabetes. IDF; 2012. Available from: http:// www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes. pdf. [Last accessed on 2015 Mar 25]
77. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
78. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 statement-Executive summary. Endocr Pract 2013;19:536-57
79. NICE Clinical Guideline Type 2 Diabetes: The Management of Type 2 Diabetes. NICE; 2009. Available from: http://www.nice.org.uk/guidance/ta203/resources/ nice-recommends-liraglutide-for-type-2-diabetes-mellitus4. [Last accessed on 2015 Mar 25]
80. SIGN. Management of Diabetes. A National Clinical Guideline. SIGN; 2010. Available from: http://www.sign.ac.uk/pdf/sign116.pdf. [Last accessed on 2015 Mar 25]
81. Amod A, Ascott-Evans BH, Berg GI, Blom DJ, Brown SL, Carrihill MM, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). The 2012 SEMDSA treatment algorithm for type 2 diabetes. J Endocrinol Metab Diabetes S Afr 2012;17 Suppl 1:S36-40
82. Japan Diabetes Society. Treatment Guideline for Diabetes; 2012-2013. Available from: http://www.jds.or.jp/modules/en/index. php?content-id=44. [Last accessed on 2015 Mar 25]
83. Chinese Diabetes Society. China Guideline for type 2 Diabetes. Chin J Diabetes 2010;2 Suppl 2:1-56
84. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-6
85. ICMR 2005. Available from: http://www.icmr.nic.in/guidelines- diabetes/section7.pdf. [Last accessed on 2015 Apr 03]
86. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994;8:201-3
87. Satoh J, Takahashi K, Takizawa Y, Ishihara H, Hirai M, Katagiri H, et al. Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 2005;70:291-7
88. Dor Y, Glaser B. And reg-cell dedifferentiation and type 2 diabetes. N Engl J Med 2013;368:572-3
89. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic ß cell dedifferentiation as a mechanism of diabetic ß cell failure. Cell 2012;150:1223-34
90. Kitamura T. The role of FOXO1 in s-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol 2013;9:615-23
91. Nyback-Nakell A, Bergström J, Adamson U, Lins PE, Landstedt-Hallin L. Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: An observational study. Diabetes Metab 2010;36:375-80
92. Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. Effect of exenatide, sitagliptin, or glimepiride on s-cell secretory capacity in early type 2 diabetes. Diabetes Care 2014;37:2451-8
93. Krentz A, Sinclair A. Do sulfonylureas still have a role in type 2 diabetes? Curr Issues 2011;22:32-6
94. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
95. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
96. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124 (1 Pt 2):136-45
97. Olsson PO, Lindström T. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002;28 (4 Pt 1):272-7
98. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: A meta-analysis. Diabetes Res Clin Pract 2000;50:S47
99. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515-22
100. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42
101. Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA (1c) and body weight in Type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003;61:13-9
102. Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: A multicentre retrospective cohort study. Diabetologia 2003;46:1611-7
103. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST study. Vasc Health Risk Manag 2014;10:319-26
104. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 2003;26:1176-80
105. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998;128:165-75
106. Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: A systematic review and meta-analysis of randomized trials. PLoS One 2014;9:e82880
107. Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res 1996;28:419-25
108. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138 (5 Pt 1):S346-52
109. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9
110. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243:450-7
111. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
112. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301
113. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-80
114. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: A systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015;3:43-51
115. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-53
116. Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: A matched case-control study. Diabetes Res Clin Pract 2008;82:391-5
117. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32:2068-74
118. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-46
119. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95:4993-5002
120. Geisen K. Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung 1988;38:1120-30
121. Raptis SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. Exp Clin Endocrinol Diabetes 1999;107:350-5
122. Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc Drugs Ther 2008;22:207-13
123. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157:601-10
124. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: A retrospective analysis. Diabetes Obes Metab 2012;14:803-9
125. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
126. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011;32:1900-8
127. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8
128. White JR, Campbell RK. Overview of medications used to treat type 2 diabetes. In: Medications for the Treatment of Diabetes. Montvale, NJ: American Diabetes Association/Thomson Reuters; 2008. p. 5-15
129. Makkar BM, Gupta D, Gainda A. Clinical Trials to Clinical Practice: Role of Sulfonylureas in Today's Practice. API Medicine. Ch. Mumbai: Jaypee Brothers; 2013. p. 393-8
130. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
131. Naidoo P, Rambiritch V, Butkow N, Saman S. Optimal utilisation of sulphonylureas in resource-constrained settings. Cardiovasc J Afr 2014;25:83-5
132. Kabadi UM. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents. Manag Care 2004;13:48-9, 53-6, 58-9
133. Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: Are newer agents better? Diabetes Care 2014;37:1338-45
134. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
135. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
136. Meece J. Improving medication adherence among patients with type 2 diabetes. J Pharm Pract 2014;27:187-94
137. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-4
138. Treatment adherence: Can fixed-dose combinations help? Lancet Diabetes Endocrinol 2015;3:91
139. Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother 2010;44:791-9
140. Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig 2014;5:701-8
141. Hiroi S, Sugiura K, Matsuno K, Hirayama M, Kuriyama K, Kaku K, et al. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. Diabetes Technol Ther 2013;15:158-65
142. Kalra S. Aggressive treatment in newly diagnosed diabetes with fixed dose combinations. API Med Update 2012;22:249-53. Available from: http://www.apiindia.org/pdf/medicine-update-2012/ diabetology-04.pdf. [Last accessed on 2015 Apr 01]
143. Pareek A, Chandurkar N, Zawar S, Agrawal N. Evaluation of efficacy and tolerability of gliclazide and metformin combination: A multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther 2010;17:559-65
144. Kalra S, Gupta Y. Sulfonylureas. J Pak Med Assoc 2015;65:101-4
145. Glyade: Gliclazide Tablets: Label Information of TGA. Available from: http://www.medicines.org.au/files/afpglyad.pdf. [Last accessed on 2015 Mar 25]
146. Diabeta: Glyburide Tablets. Label Information of FDA. Available from: http://www.accessdata.fda.gov/drugsatfda- docs/label/2013/017532Orig1s034lbl.pdf. [Last accessed on 2015 Mar 25]
147. Amaryl: Glimepiride Tablets. Label Information of FDA. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/020496s027lbl.pdf. [Last accessed on 2015 Mar 25]
148. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8
149. Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med 2005;33:519-23
150. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study. Diabetes Care 2007;30:790-4
151. Benaji B, Mounib N, Roky R, Aadil N, Houti IE, Moussamih S, et al. Diabetes and Ramadan: Review of the literature. Diabetes Res Clin Pract 2006;73:117-25
152. Fariduddin M, Mahtab H, Latif ZA, Siddiqui NI. Practical management of diabetes during Ramadan fasting. Mymensingh Med J 2011;20:541-6
153. Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2
154. Zargar AH, Siraj M, Jawa AA, Hasan M, Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract 2010;64:1090-4
155. Bashir MI, Pathan MF, Raza SA, Ahmad J, Khan AK, Ishtiaq O, et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab 2012;16:503-7
156. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58
157. Glucotrol: Glipizide Tablets. Label Information of FDA. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/017783s025lbl.pdf. [Last accessed on 2015 Mar 25]
158. Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 2014;10:839-57
159. Wosilait WD. An analysis of the effect of hypoalbuminemia on the amount of free drug in plasma for drugs bound at two sets of sites. Res Commun Chem Pathol Pharmacol 1974;9:681-8
160. Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med 2012;124:130-7
161. Campbell I. Sulfonylureas and hypoglycemia. Diabet Hypoglycemia 2009;2:3-10
162. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig 2014;5:475-7